243 related articles for article (PubMed ID: 4181594)
1. Localization of the oxidative defect in phytanic acid degradation in patients with Refsum's disease.
Mize CE; Herndon JH; Blass JP; Milne GW; Follansbee C; Laudat P; Steinberg D
J Clin Invest; 1969 Jun; 48(6):1033-40. PubMed ID: 4181594
[TBL] [Abstract][Full Text] [Related]
2. In vivo study of phytanic acid alpha-oxidation in classic Refsum's disease and chondrodysplasia punctata.
ten Brink HJ; Schor DS; Kok RM; Stellaard F; Kneer J; Poll-The BT; Saudubray JM; Jakobs C
Pediatr Res; 1992 Nov; 32(5):566-70. PubMed ID: 1282700
[TBL] [Abstract][Full Text] [Related]
3. Refsum's disease: nature of the enzyme defect.
Steinberg D; Herndon JH; Uhlendorf BW; Mize CE; Avigan J; Milne GW
Science; 1967 Jun; 156(3783):1740-2. PubMed ID: 4180573
[TBL] [Abstract][Full Text] [Related]
4. Studies on the metabolic error in Refsum's disease.
Steinberg D; Mize CE; Avigan J; Fales HM; Eldjarn L; Try K; Stokke O; Refsum S
J Clin Invest; 1967 Mar; 46(3):313-22. PubMed ID: 4164676
[TBL] [Abstract][Full Text] [Related]
5. Peroxisomes, Refsum's disease and the alpha- and omega-oxidation of phytanic acid.
Wanders RJ; Komen JC
Biochem Soc Trans; 2007 Nov; 35(Pt 5):865-9. PubMed ID: 17956234
[TBL] [Abstract][Full Text] [Related]
6. Disorders related to the metabolism of phytanic acid.
Stokke O; Skjeldal OH; Høie K
Scand J Clin Lab Invest Suppl; 1986; 184():3-10. PubMed ID: 2438746
[TBL] [Abstract][Full Text] [Related]
7. Refsum's disease: characterization of the enzyme defect in cell culture.
Herndon JH; Steinberg D; Uhlendorf BW; Fales HM
J Clin Invest; 1969 Jun; 48(6):1017-32. PubMed ID: 4181593
[TBL] [Abstract][Full Text] [Related]
8. Phytanic acid alpha-oxidation: accumulation of 2-hydroxyphytanic acid and absence of 2-oxophytanic acid in plasma from patients with peroxisomal disorders.
ten Brink HJ; Schor DS; Kok RM; Poll-The BT; Wanders RJ; Jakobs C
J Lipid Res; 1992 Oct; 33(10):1449-57. PubMed ID: 1385561
[TBL] [Abstract][Full Text] [Related]
9. The metabolic basis of the Refsum syndrome.
Steinberg D
Birth Defects Orig Artic Ser; 1971 Feb; 7(1):42-52. PubMed ID: 4141910
[TBL] [Abstract][Full Text] [Related]
10. Phytanic acid and very long chain fatty acids in genetic peroxisomal disorders.
Molzer B; Kainz-Korschinsky M; Sundt-Heller R; Bernheimer H
J Clin Chem Clin Biochem; 1989 May; 27(5):309-14. PubMed ID: 2474624
[TBL] [Abstract][Full Text] [Related]
11. Phytanic acid and pristanic acid, branched-chain fatty acids associated with Refsum disease and other inherited peroxisomal disorders, mediate intracellular Ca2+ signaling through activation of free fatty acid receptor GPR40.
Kruska N; Reiser G
Neurobiol Dis; 2011 Aug; 43(2):465-72. PubMed ID: 21570468
[TBL] [Abstract][Full Text] [Related]
12. Refsum's disease: defective oxidation of phytanic acid in tissue cultures derived from homozygotes and heterozygotes.
Herndon JH; Steinberg D; Uhlendorf BW
N Engl J Med; 1969 Nov; 281(19):1034-8. PubMed ID: 4188238
[No Abstract] [Full Text] [Related]
13. Fatty acid composition of tissues in Refsum's disease (herodopathia atactica polyneuritiformis). Estimation of total phytanic acid accumulation.
Malmendier CL; Jonniaux G; Voet W; Van Den Bergen CJ
Biomedicine; 1974 Nov; 20(6):398-407. PubMed ID: 4141904
[No Abstract] [Full Text] [Related]
14. CYP4 isoform specificity in the omega-hydroxylation of phytanic acid, a potential route to elimination of the causative agent of Refsum's disease.
Xu F; Ng VY; Kroetz DL; de Montellano PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):835-9. PubMed ID: 16707724
[TBL] [Abstract][Full Text] [Related]
15. The nature of the metabolic defect in Refsum's disease.
Steinberg D; Avigan J; Mize CE; Herndon JH; Fales HM; Milne GW
Pathol Eur; 1968; 3(2):450-8. PubMed ID: 4176998
[No Abstract] [Full Text] [Related]
16. Accumulation and defective beta-oxidation of very long chain fatty acids in Zellweger's syndrome, adrenoleukodystrophy and Refsum's disease variants.
Poulos A; Singh H; Paton B; Sharp P; Derwas N
Clin Genet; 1986 May; 29(5):397-408. PubMed ID: 2427264
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and biochemical follow up of Refsum's disease (author's transl)].
Barolin GS; Hodkewitsch E; Höfinger E; Scholz H; Bernheimer H; Molzer B
Fortschr Neurol Psychiatr Grenzgeb; 1979 Feb; 47(2):53-66. PubMed ID: 84779
[TBL] [Abstract][Full Text] [Related]
18. Long-term strategies for the treatment of Refsum's disease using therapeutic apheresis.
Zolotov D; Wagner S; Kalb K; Bunia J; Heibges A; Klingel R
J Clin Apher; 2012; 27(2):99-105. PubMed ID: 22267052
[TBL] [Abstract][Full Text] [Related]
19. Phytanic acid levels in serum and central nervous system in Refsum's disease.
Dereux J; Lowenthal A; Mardens Y; Karcher D
Pathol Eur; 1968; 3(2):468-73. PubMed ID: 4177000
[No Abstract] [Full Text] [Related]
20. Evidence against alpha-hydroxyphytanic acid as an intermediate in the metabolism of phytanic acid.
Skjeldal OH; Stokke O
Scand J Clin Lab Invest; 1988 Feb; 48(1):97-102. PubMed ID: 2464193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
